Caspofungin for treatment of invasive aspergillus infections

Mycoses

Volumn 51, Issue SUPPL. 1, 2008, Pages 47-57

  Heinz, W J ^a   Einsele, H ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Antifungal therapy; Aspergillus; Caspofungin; Invasive aspergillosis; Salvage therapy

Indexed keywords

AMBILOAD; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ASPERGILLOSIS; ASPERGILLUS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG USE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MONOTHERAPY; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; VISUAL DISORDER;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CLINICAL TRIALS AS TOPIC; ECHINOCANDINS; HEMATOLOGIC DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION; TREATMENT OUTCOME;

ASPERGILLUS;

EID: 43549110280     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01528.x     Document Type: Review

References (51)

1. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995 171 : 1545 52.
2. Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992 326 : 845 51.
3. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004 103 : 1527 33.
4. Glockner A, Vehreschild JJ, Cornely OA. Zygomycosis - current epidemiological aspects. Mycoses 2007 50 : 50 5.
5. Maschmeyer G, Haas A. The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents 2008 31 : 193 7.
6. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005 191 : 1350 60.
7. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002 34 : 909 17.
8. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005 56 (Suppl. 1 i5 i11.
9. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 34 : 7 14.
10. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006 91 : 986 9.
11. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007 44 : 373 9.
12. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 15.
13. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007 44 : 1289 97.
14. Herbrecht R, Fluckiger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. European Journal of Cancer Supplements, Guidelines from the First European Conference on Infections in Leukaemia: ECIL1 2007 5 : 49 59.
15. Walsh T, Anaissie E, Denning D et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008 46 : 327 60.
16. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 50 : 1570 2.
17. Trifilio S, Pennick G, Pi J et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007 109 : 1532 5.
18. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006 53 : 337 49.
19. Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005 50 : 196 205.
20. ©, Itraconazole (I) or Voriconazole (V); P-029. Las Vegas, Nevada : Focus on Fungal Infections 16th Annual Conference, Nevada, 2006.
21. Groetzner J, Kaczmarek I, Wittwer T et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 2008 27 : 1 6.
22. Bonini A, Tieghi A, Gugliotta L. First line antifungal treatment with Caspofungin of Oncohemopatic Patients. A Single Centre Experience. Blood 2006 108 : 5271.
23. Viscoli C, Herbrecht R, Akan H et al. Caspofungin (C) as first-line therapy of invasive aspergillosis (IA) in haematological patients (pts): a study of the EORTC Infectious Diseases Group. TIMM (Trends in Medical Mycology). Torino, 2007.
24. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002 35 : 359 66.
25. Kohno S, Masaoka T, Yamaguchi H et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004 36 : 372 9.
26. Walsh TJ, Lutsar I, Driscoll T et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002 21 : 240 8.
27. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 44 : 2 12.
28. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006 107 : 2888 97.
29. Morrissey CO, Slavin MA, O'Reilly MA et al. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. Mycoses 2007 50 (Suppl. 1 24 37.
30. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 34 : 563 71.
31. Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 26 : 1383 96.
32. Glasmacher A, Cornely OA, Orlopp K et al. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J Antimicrob Chemother 2006 57 : 127 34.
33. Petrovic J, Ngai A, Bradshaw S et al. Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant Proc 2007 39 : 3117 20.
34. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003 98 : 292 9.
35. Caillot D, Thiebaut A, Herbrecht R et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007 110 : 2740 6.
36. Aliff TB, Maslak PG, Jurcic JG et al. Refractory aspergillus pneumonia in patients with acute leukemia. Cancer 2003 97 : 1025 32.
37. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004 39 : 797 802.
38. Marr K. Combination antifungal therapy: where are we now, and where are we going? Oncology 2004 18 : 24 9.
39. Marr K, Boeckh M, Kim H. Reply to Cesaro and Visintin. Clin Infect Dis 2005 40 : 1075 6.
40. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004 34 : 13 20.
41. Raad II, Hanna HA, Boktour M et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008 22 : 496 503.
42. Herbrecht R, Flückiger U, Gachot B, Ribaud B, Thiebaut A, Cordonnier C. 2007 update of the ECIL-1 guidelines for Antifungal therapy in leukemia patients, URL http://www.leukemia-net.org/content/e70/e142/e272/e4702/ infoboxContent5847/ECIL2_Antifungaltherapy.pdf?raw=ecil&ZMS_HIGHLIGHT=raw, 2008.
43. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 356 : 348 59.
44. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007 356 : 335 47.
45. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 32 : 358 66.
46. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000 79 : 250 60.
47. Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002 46 : 3208 14.
48. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 351 : 1391 402.
49. Candoni A, Mestroni R, Damiani D et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 2005 75 : 227 33.
50. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 71.
51. Tischer J, Schiel X, Rieger C et al. Anti-fungal combination therapy for the treatment of invasive aspergillosis in patients undergoing allogeneic stem cell transplantation. 30th Annual Meeting of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 2004 44 (Suppl. 1).